Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Google, Sanofi team up to improve diabetes care

Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google’s life sciences team to collect, analyze and understand information impacting diabetes, which is expected to affect 592 million by 2035, according to the International Diabetes Federation. Sanofi’s diabetes product […]

Read More »

Right Place, Right Time: How Health Care and Wellness Companies Are Capitalizing on the Rapidly Growing Point of Care Communication Channel

Point of care (POC) communications, a historically small piece of the consumer-facing communications mix for health and wellness vendors in the U.S. represents a growing opportunity for brands to reach patients and caregivers in settings where they are especially focused on their health and wellness: at the doctor’s office, pharmacy and hospital.

Read More »

Bristol-Myers buys rights to acquire fibrosis drug developer

Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. PRM-151 is […]

Read More »

Pfizer to Terminate a Large Number of Employees in Korea

NEW YORK – Pfizer Inc.[2] (PFE[3]) is looking to terminate a number of its Korea-based employees as a means to increase efficiency in its management positions, Streetwise reported[4] this morning. The possible terminations come at a time when the small Korean branch has consistently shown strong growth despite a slowdown elsewhere, Streetwise said. Pfizer has […]

Read More »

Medtronic says trials find gene linked to sudden cardiac death

Two studies have identified a gene associated with potentially fatal abnormal heart rhythms, device maker Medtronic Plc said on Monday. The studies evaluated genetic information to identify gene abnormalities that may be associated with heart rhythms that could cause sudden cardiac death, the company said. Sudden cardiac death (SCD) is an unexpected death caused by […]

Read More »

Asterias’ stem cell therapy shows promise in study

Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans. Its success is a key step toward proving that embryonic […]

Read More »

Amicus Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million

CRANBURY, N.J. – Amicus Therapeutics, Inc. (FOLD) inked a deal to acquire the privately-held biopharmaceutical company Scioderm Inc., Inc. in a deal worth up to $847 million, the company announced this morning.   The acquisition places Scioderm’s lead product candidate Zorblisa, a topical cream for the treatment of Epidermolysis Bullosa (EB) into Amicus’ rare and […]

Read More »

Bayer moves heart drug to final tests after mid-stage success

Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial. Having done well with recently launched drugs like stroke prevention pill Xarelto and eye treatment Eylea, the German group is eager to […]

Read More »

Texas teen dies of rare brain-eating amoeba infection

A Texas teenager who contracted a rare brain-eating disease after swimming in a lake about 70 miles (110 km) north of Houston has died, according to his family and local media. The 14-year-old Michael Riley Jr., a junior Olympian and honor student, seemed to have contracted the disease after he went swimming on Aug. 13 […]

Read More »

Alnylam, Medicine Co.’s cholesterol drug lasts months after one shot

A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam Pharmaceuticals and Medicines Co’s experimental product ALN-PCSsc highlight the competition for a market tipped […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom